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LETTERS TO THE EDITOR
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More recent results now indicate that glucocorticoid
drugs, frequently administered in transplanted patients,
Continuous renalrepresent this yet unknown “cystatin C increasing fac-
tor.” A case-control study in kidney transplant recipients
observed that glucocorticoid administration in a dose- replacement therapy versus
dependent manner leads to increased cystatin C concen-
trations [3]. These findings do not preclude the use of intermittent hemodialysis in
cystatin C in detecting impaired renal function, since this
study [3] and others [4, 5] revealed cystatin C to be acute renal failure
significantly more accurate in detecting impaired renal
function in kidney transplant recipients receiving gluco-
To the Editor: I commend Mehta et al [1] for theircorticoids. Moreover, the need for specific reference
recent article in Kidney International. They confirmedranges in patients with glucocorticoid therapy is clearly
that severity of illness, but not the modality of renal re-demonstrated.
placement therapy (RRT), is the major determinant ofIt must be emphasized that glucocorticoid administa-
mortality, and that sicker patients tend to get continuoustion so far has not been included into data analysis of
renal replacement therapy (CRRT).studies evaluating cystatin C as a marker of impaired
Their optimistic expectation of 28.5% mortality dif-renal function. Depending on the investigated collective,
ference, and 50% observed mortality (versus 70% pre-a bias in data interpretation therefore is likely to have
dicted), hampers their power. Choosing a smaller differ-occurred. In summary, to avoid underestimation of glo-
ence would have increased the sample size and wouldmerular filtration rate in clinical routine settings as well
have avoided the possibility of missing a smaller differ-as in future clinical studies, it is important to take gluco-
ence. It was unfair to exclude hypotensive patients whocorticoid medication in account when interpreting cy-
could have benefited more by CRRT.statin C levels in renal transplant patients, and, presum-
As solute clearance may influence the outcome, theably, in other patient collectives.
relevance of their results to currently proposed higher
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Interestingly, 21% of patients (11% died, renal func-
tion improved in 10%) either did not receive or received
a short course of RRT, underscoring the difficulty of ap- 2002 by the International Society of Nephrology
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